IGF::OT::IGF: SBIR PHASE II, TOPIC 326: DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS

IGF::OT::IGF：SBIR 第二阶段，主题 326：开发针对癌症干细胞的新型治疗药物

• 批准号: 9361081
• 负责人: DR. TZUYIN (CINDY) LIN
• 金额: $ 150万
• 依托单位: LP THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2018-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9361081
• 关键词: Acute Myelocytic Leukemia; Adverse effects; Cardiotoxicity; Cells; Clinical trial protocol document; Cyclic GMP; Daunorubicin; Development; Dose; Goals; Hematopoietic stem cells; Human; Micelles; Natural regeneration; Normal Cell; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Plant Roots; Property; Recurrence; Resistance; Small Business Innovation Research Grant; Stem cells; Therapeutic Agents; Toxic effect; Xenograft procedure; cancer stem cell; chemotherapy; leukemia; leukemic stem cell; mouse model; nanoscale; novel therapeutics

The goal of this project is to develop nanometer-scale micelles to deliver high concentration of the chemotherapeutic drug daunorubicin (DNR) directly into acute myeloid leukemia (AML) stem cells (LSCs) and eradicate AML from the very root. LSCs are a special group of leukemia cells that are relatively resistant to conventional doses of chemotherapy, can regenerate more leukemia cells and cause leukemia recurrence.

该项目的目标是开发纳米级胶束，将高浓度的化疗药物柔红霉素（DNR）直接输送到急性髓系白血病（AML）干细胞（LSC）中，并从根本上根除AML。LSC是一组特殊的白血病细胞，它们对常规剂量的化疗相对耐受，可以再生更多的白血病细胞并导致白血病复发。